Roche Holding (OTCQX:RHHBY): FY Non-GAAP EPS of CHF20.16; GAAP EPS of CHF15.62.
Revenue of CHF61.47B (+8.1% Y/Y)
https://seekingalpha.com/news/3536173-roche-holding-reports-fy-results
Thursday, January 30, 2020
Thermo Fisher slips on Q4 earnings
Thermo Fisher Scientific (TMO)
Q4 results: Revenues: $6,829M (+4.9%); Life Sciences Solutions: $1,838M
(+8.3%); Analytical Instruments: $1,518M (-3.2%); Specialty
Diagnostics: $939M (-1.3%); Laboratory Products and Services: $2,834M
(+8.9%).
Net Income: $1,002M (+11.6%); EPS: $2.49 (+12.2%); non-GAAP Net Income: $1,428M (+8.4%); non-GAAP EPS: $3.55 (+9.2%).
CF Ops: $4,973M (+9.5%).
https://seekingalpha.com/news/3536181-thermo-fisher-slips-1-premarket-on-q4-earnings
AmerisourceBergen EPS beats by $0.09, revenue in-line
AmerisourceBergen (NYSE:ABC): Q1 Non-GAAP EPS of $1.76 beats by $0.09; GAAP EPS of $0.90 misses by $0.63.
Revenue of $47.86B (+5.4% Y/Y) in-line.
https://seekingalpha.com/news/3536183-amerisourcebergen-eps-beats-0_09-revenue-in-lineAlexion Pharmaceuticals EPS beats by $0.10, beats on revenue
Alexion Pharmaceuticals (NASDAQ:ALXN): Q4 Non-GAAP EPS of $2.71 beats by $0.10; GAAP EPS of $4.00 beats by $1.91.
Revenue of $1.38B (+22.1% Y/Y) beats by $60M.
https://seekingalpha.com/news/3536184-alexion-pharmaceuticals-eps-beats-0_10-beats-on-revenueQuest Diagnostics EPS beats by $0.07, beats on revenue
Quest Diagnostics (NYSE:DGX): Q4 Non-GAAP EPS of $1.67 beats by $0.07; GAAP EPS of $1.86 beats by $0.54.
Revenue of $1.93B (+4.9% Y/Y) beats by $10M.
https://seekingalpha.com/news/3536200-quest-diagnostics-eps-beats-0_07-beats-on-revenueEli Lilly +1% premarket on Q4 beat; raises revenue guidance
Eli Lilly (LLY) Q4 results: Revenues: $6,114M (+8.5%).
Net Income: $1,495.7M (+32.9%); EPS: $1.64 (+49.1%); non-GAAP Net Income: $1,583.3M (+25.8%); non-GAAP EPS: $1.73 (+31.1%).
Key product sales: Trulicity: $1,208.1M (+31%);
Humalog: $763.4M (-1%); Alimta: $530.7M (-5%); Forteo: $360.2M (-18%);
Taltz: $420.1M (+37%); Humulin: $348.0M (+3%); Basaglar: $307.2M (+32%);
Jardiance: $268.0M (+39%); Cyramza: $245.1M (+11%); Cialis: $197.8M
(-44%); Emgality: $66.3M.
2020 guidance: Revenue: $23.7B – 24.2B from $23.6B – 24.1B; EPS: $6.18 – 6.28 from $6.38 – 6.48; non-GAAP EPS: $6.70 – 6.80 (unch).
Shares are up 1% premarket.
Previously: Eli Lilly EPS beats by $0.21, beats on revenue (Jan. 30)
https://seekingalpha.com/news/3536226-eli-lillyplus-1-premarket-on-q4-beat-raises-revenue-guidanceLilly baricitinib successful in fourth late-stage dermatitis study
Eli Lilly (NYSE:LLY) and licensor Incyte (NASDAQ:INCY) announce positive results from another Phase 3 clinical trial, BREEZE-AD5, evaluating two strengths of oral JAK inhibitor baricitinib in adults with moderate-to-severe atopic dermatitis (AD).
The 1 mg dose failed to hit the primary endpoint
of a statistically significant proportion of patients achieving at least
a 75% improvement in AD (EASI75) at week 16 versus placebo.
The 2 mg dose was successful. 29.5% (n=43/146) of
treated patients achieved EASI75 compared to 8.2% (n=12/147) in the
control arm (p=0.001).
No new safety signals were observed.
Complete results will be submitted for presentation at future medical conferences and publication.
Three previous late-stage studies, BREEZE-AD1, AD2 and AD7, were also successful.
Lilly recently filed a marketing Europe. It expects to submit applications in the U.S. and Japan this year.
LLY is up 1% premarket.
https://seekingalpha.com/news/3536233-lilly-baricitinib-successful-in-fourth-late-stage-dermatitis-study
Subscribe to:
Posts (Atom)